No Data
Kojima ETC [buy demand for next week]
[Demand for Buying Next Week (Table)] Code; Stock Name; Stock Price Impact; Buy Demand; Credit Ratio; Closing Price; Change from Previous Day <7925>; Pawasa Chemical; 362%; 135,300; 0.04; 1,755; -5 <8179>; Royal HD; 226%; 392,000; 0.06; 2,465; 16 <3028>; Alpen; 160%; 161,100; 0.06; 2,038; 13 <1914>; Nikiso; 148%; 13,200; 13.99; 597; 1 <2404>; Iron Man
Stocks that moved the previous day part1 ABC Mart, Levin T, Aiz etc.
Stock Name <Code> Closing Price on the 4th ⇒ Change from Previous Day * ABC Mart ＜2670＞ 3194 +541 Same-store sales in November increased by 14.7%, expanding from a 6.3% increase in October. * Fujidenki ＜6654＞ 1101 -50 Operating profit for the cumulative third quarter decreased by 1.9%, shifting from a 9.8% increase in the first half. * Mitsukoshi Isetan ＜3099＞ 2366 +142.5 Reports indicate that the requirements for visa issuance for Chinese tourists will be relaxed, leading to a market focus on inbound-related stocks in the afternoon. * IGS ＜4265＞ 332
Active and newly established stocks in the afternoon session.
*ABC Mart <2670> 3194 +541, same-store sales in January increased by 14.7% compared to 6.3% in October, showing an expanded growth rate. *Fujidenki <6654> 1101 -50, operating profit for the third quarter decreased by 1.9% compared to 9.8% increase in the previous period, resulting in a profit decline. *Mitsukoshi Isetan <3099> 2366 +142.5, reports of easing requirements for Chinese visas led afternoon trading to focus on inbound-related activities. *IGS <4265> 332 +29, Ministry of Education's cutting-edge technology and edu.
December 4th [Today's Investment Strategy]
[FISCO Selected Stocks] [Material Stocks] JCR Pharma <4552> 727 yen (12/3) Human growth hormone preparations are the main products. Regarding the blood-brain barrier crossing type α-N-acetylglucosaminidase preparation (JR-446) developed by the company, the first administration to the first subject targeted at mucopolysaccharidosis type 3B (MPS3B) in clinical phase 1/2 trials in Japan was announced. MPS3B is being jointly developed and commercialized with Medipal Holdings <7459>.
Pay attention to JCR Pharma and ABC Mart, while Uchida Yoko and Tsukishima HD may be sluggish.
In the U.S. stock market on the 3rd of yesterday, the dow jones industrial average decreased by 76.47 dollars, closing at 44,705.53, the nasdaq rose by 76.96 points to 19,480.91, and the Chicago Nikkei 225 futures increased by 90 yen compared to during the day in Osaka, reaching 39,240 yen. The exchange rate is 1 dollar = 149.50-150.00 yen. In today's Tokyo market, the same-store sales for November increased by 14.7%, expanding from the 6.3% growth in October for ABC Mart <2670>, and the same-store sales for November rose by 8.9%, compared to the 6.3% in October.
Uchida Yoko, 1Q operating profit decreased by 48.6% to 1.537 billion yen
Yucho＜8057＞ announced that the first quarter performance for the July 2025 period showed a 1.2% decrease in revenue compared to the same period last year, amounting to 52.5 billion63 million yen, and a 48.6% decrease in operating profit to 1.5 billion37 million yen. Due to a focus on system renovation projects to adapt to the invoicing system and significant impact from large mainland education ICT projects, both revenue and gross profit decreased. Progress is being made on employee treatment improvements such as the Group's common sales management system investment and base up. Thus, the sales expenses are being managed accordingly.
No Data